Tranylcypromine Oral Tablet [Parnate]
RxNorm 369259
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 369259 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: tranylcypromine Oral Tablet [Parnate].
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
Semantic Branded Drug Form (SBDF):
Tranylcypromine Oral Tablet [Parnate]
(Atom ID: 12319598)
Patient Education
Tranylcypromine
Tranylcypromine is used to treat depression in people who have not been helped by other medications. Tranylcypromine is in a class of medications called monoamine oxidase inhibitors (MAOIs). It works by increasing the amounts of certain natural substances that are needed to maintain mental balance.
[Learn More]
Antidepressants
Antidepressants are medicines that treat depression. Your doctor can prescribe them for you. They work to balance some of the natural chemicals in our brains. It may take several weeks for them to help. There are several types of antidepressants. You and your doctor may have to try a few before finding what works best for you.
Antidepressants may cause mild side effects that usually do not last long. These may include headache, nausea, sleep problems, restlessness, and sexual problems. Tell your doctor if you have any side effects. You should also let your doctor know if you take any other medicines, vitamins, or herbal supplements.
It is important to keep taking your medicines, even if you feel better. Do not stop taking your medicines without talking to your doctor. You often need to stop antidepressants gradually.
NIH: National Institute of Mental Health
[Learn More]
* Please review the disclaimer below.